CSL Limited: PharmaVitae Profile

Datamonitor, December 2010, Pages: 58

Introduction

This analysis examines the historical and forecast performance for CSL in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

- Gain insight into CSL's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for CSL over the next six years.
Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

- Benchmark CSL's performance against key rivals in the prescription pharmaceutical sector
- Assess the importance of the recently launched Hizentra to CSL's topline growth over the forecast period

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–
Financial performance, 2003–
CSL: PharmaVitae forecasts at a glance
Strategic insight
Acquisition of Aventis Behring made CSL a truly global player
Hizentra; CSL leads the subcutaneous Ig market
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q2
Q1
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Current corporate structure
[Missing title]
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–
Product analysis
Product analysis, 2003–
Product analysis, 2009–
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Launch/core/expiry configuration, 2009–
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–
Operating costs and profit analysis
Operating costs and profit analysis, 2003–
Operating cost ratio and profit margin analysis, 2003–
Operating cost ratio and profit margin analysis, 2009–
Operating costs and profit analysis, 2009–
APPENDIX
Abbreviations
Exchange rates

Customers who bought this item also bought

• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Sports and Fitness Nutrition - Global Strategic Business Report
• The 111th U.S. Congress Tackles Healthcare Reform and the Pharmaceutical Industry
• Aerospace and Defence Industry - Global Strategic Business Report
• Aerospace and Defense Industry - Global Outlook
• Distance Learning - Global Outlook
• Israel Life Sciences Market Analysis
• Aerospace and Defense Industry - Global Strategic Business Report
• Global and China Military Industry Report, 2009-2010
• Global and China Military Industry Report, 2009-2010